

PATIENT ADVISORY BOARD AGREEMENT

This Agreement (“**Agreement**”) is effective from the date of the last signature between Novartis Healthcare A/S (Reg. No. 20575786), Edvard Thomsens Vej 14, 2300 København S, Denmark (“**Novartis**”) and Patientforeningen Lungekræft (represented by Lisbeth Søbæk Hansen), Industrivej 21, 4000 Roskilde (“**Patient**”).

WHEREAS Novartis is committed to patient centricity and in particular to better understand patients’ experience with their disease, how patients interact with their physicians, and how Novartis can be responsive to their questions and needs;

WHEREAS, for this purpose, Novartis is conducting internal events, for Novartis employees and Novartis management, inviting patients, their caregivers and physicians to share their experience on a disease, how it affects their life, and on related healthcare issues.

WHEREAS Patient is willing to take part in one of such events, and to provide her personal patient perspective of what the Danish cancer patient community expect from Novartis as a Global patient centric pharma company, and what more Novartis Oncology can do to create value for cancer patients in Denmark.

In witness thereof, the parties agree as follows:

1. Patient agrees to participate in a Kræftpatientens udfordringer i det danske sundhedsvæsen advisory board. In the meeting, she will take an active part in the discussions on the following topics: (“**the Speaking Engagement**”).
 - Patientens udfordringer i mødet med sundhedssystemet, herunder:
 - Hvilke udfordringer hører I tysik om fra patienterne?
 - Hvilke udfordringer frustrerer jer?
 - Hvornår i sygdomsforløbet der der flest udfordringer?

The meeting will take place on 12. November 2020 på Comfort Hotel Vesterbro, Vesterbrogade 23-29, 1620 København (“**the Event**”)

2. Patient confirms that the advisory board service in her own free will and accord. Any information that Patient will communicate during the Event will be accurate to the best of Patient’s knowledge, and will reflect Patient’s personal true and honest opinion of her experience and that Novartis shall not be responsible for any statement made by Patient during the Event.
3. Any information relating to Novartis or its affiliates or any of its or their businesses, business plans, operations or products acquired by Patient in the course of this Agreement (“**Information**”) will be kept strictly confidential by Patient and will not be

Patient Speaker Agreement Template Denmark Legal Approved 21 September 2018

used by Patient except as necessary to provide the Speaking Engagement. Patient shall not disclose, whether in writing or orally, any Information, including the existence and contents of this Agreement, to any third party without Novartis' prior written consent. These obligations will remain in force after expiry of this Agreement. Upon request of Novartis, Patient shall promptly return to Novartis or destroy any documents and computer data containing any Information, and any materials supplied by Novartis.

The obligations specified in this Section shall not apply to Information which Patient can demonstrate by written evidence: (a) is (at the time of disclosure) or becomes (after the time of disclosure) known to the public through no breach of any obligations by Patient; (b) is disclosed to Patient by a third party who is entitled to disclose it without breaching a confidentiality obligation; (c) was known to, or otherwise in the possession of, Patient prior to the time of disclosure by Novartis; or (d) is developed by Patient independently of any information disclosed by Novartis or its affiliates.

Patient may also disclose such Information if compelled to do so by a court, administrative agency or other tribunal of competent jurisdiction; provided however, that Patient shall first provide prompt written notice to Novartis of such requirement so that Novartis may seek a protective order or other remedy from such court, agency or tribunal and Patient shall only disclose that portion of the Information that, in the reasonable opinion of its legal counsel, is required to be disclosed.

4. In appreciation of the advisory board service, Novartis agrees to pay an amount of **2250 DKK** as compensation. If cancellation of the advisory board before the actual event, Novartis will not pay any compensation.
5. In addition, Novartis agrees to reimburse reasonable out-of-pocket expenses actually incurred by Patient in providing the Advisory board service (such as but not limited to travel expenses in accordance with Novartis' travel policy and courier charges). Reimbursement of such expenses is subject to production of receipts or other evidence of payment and the written pre-approval of Novartis.
6. This Agreement shall be construed by and enforced in accordance with the laws of Denmark without regard to its principles of conflicts of law. The parties hereby submit to the exclusive jurisdiction of and venue in the ordinary courts located in Copenhagen, Denmark.
7. This Agreement constitutes the entire understanding between the parties with respect to its subject matter and shall supersede any other prior arrangements as to the Speaking Engagement.

IN WITNESS WHEREOF, the parties intending to be bound have caused this Agreement to be executed.

Patient organization

I understand and agree with the terms and conditions of this Agreement.

I am not obligated in any way to sign this Agreement and I am signing it voluntarily.

Name: Lisbeth Søbæk Hansen

Title: Formand

Patient organization: Patientforeningen Lungekræft

Date: 01-nov-20 | 7:19:19 AM EST

Signature:

DocuSigned by:
Lisbeth Søbæk Hansen
BF9BAA7ECA9840D...

NOVARTIS HEALTHCARE AS

Contract owner

Name: Rikke Sonne Hansen

Title: Medical Advisor

Oncology, Denmark

Business Approver

Name: Anders Jespersen

Title: Medical Head

Oncology, Denmark

Date: 28-okt-20 | 12:10:21 PM GMT

Signature:

DocuSigned by:
Rikke Sonne Hansen
8B63D08C9C0E4B0...

Date: 30-oct-20 | 2:06:29 PM GMT

Signature:

DocuSigned by:
Anders Jespersen
CB44058A7F694BA...

Certifikat for færdiggørelse

Kuvert-id: 7ECCA7457F6F4DF58A6E7A6982EA0C01	Status: Gennemført
Emne: Please DocuSign: Patient Agreement_Danish Patient Advisory Board_Lisbeth Søbæk Hansen.docx	
Kildekuvert:	
Dokumentsider: 3	Underskrifter: 3
Certifikatsider: 5	Initialer: 0
Autonavagation: Aktiveret	Kuvertskaber:
Kuvertstempling: Aktiveret	Lene Larsson
Tidszone: (UTC-05:00) Eastern Time (US & Canada)	Novartis Pharma AG
	P.O Box CH - 4002
	Basel, Basel-City 4002
	lene.larsson@novartis.com
	IP-adresse: 160.62.7.250

Sporing af poster

Status: Original	Ihændeager: Lene Larsson	Sted: DocuSign
28-10-2020 08:01:02	lene.larsson@novartis.com	
Status for sikkerhedsenheder: Tilsluttet	Samling: Novartis	

Hændelser for underskriver

Anders Jespersen
anders.jespersen@novartis.com
Novartis
Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

Underskrift

DocuSigned by:
Anders Jespersen
CB44058A7F694BA...

Vælg underskrift: Forudvalgt stil
Brug af IP-adresse: 160.62.7.250

Tidsstempel

Sendt: 28-10-2020 08:03:44
Vist: 30-10-2020 10:05:40
Signeret: 30-10-2020 10:06:29

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via DocuSign

Rikke Sonne Hansen
rikke_sonne.hansen@novartis.com
Novartis
Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

DocuSigned by:
Rikke Sonne Hansen
8B63D08C9C0E4B0...

Vælg underskrift: Forudvalgt stil
Brug af IP-adresse: 160.62.7.250

Sendt: 28-10-2020 08:03:44
Vist: 28-10-2020 08:08:34
Signeret: 28-10-2020 08:10:21

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via DocuSign

Lisbeth Søbæk Hansen
info@lungekraeft.com
Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

DocuSigned by:
Lisbeth Søbæk Hansen
BF98AA7ECA9840D...

Vælg underskrift: Forudvalgt stil
Brug af IP-adresse: 188.179.127.11

Sendt: 30-10-2020 10:06:30
Vist: 01-11-2020 07:18:50
Signeret: 01-11-2020 07:19:19

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 01-11-2020 07:18:50
Id: 0b686253-1a09-4226-a3a5-674223720a5f

Hændelser for personlig underskriver	Underskrift	Tidsstempel
Hændelser for redaktørlevering	Status	Tidsstempel
Hændelser for agentlevering	Status	Tidsstempel
Hændelser for midlertidig levering	Status	Tidsstempel

Hændelser for certificeret levering	Status	Tidsstempel
-------------------------------------	--------	-------------

Hændelser for kopi (cc:)	Status	Tidsstempel
--------------------------	--------	-------------

Vidnehændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Notarhændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Hændelser for kuvertoversigt	Status	Tidsstempler
------------------------------	--------	--------------

Kuvert sendt	Med hash/krypteret	28-10-2020 08:03:44
Leveret certificeret	Sikkerhedskontrolleret	01-11-2020 07:18:50
Signering fuldført	Sikkerhedskontrolleret	01-11-2020 07:19:19
Gennemført	Sikkerhedskontrolleret	01-11-2020 07:19:19

Betalingshændelser	Status	Tidsstempler
--------------------	--------	--------------

Oplysninger om elektroniske poster og underskrifter

CONSUMER DISCLOSURE

From time to time, Novartis (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Novartis:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise Novartis of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

To request paper copies from Novartis

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. Please print the online copy of the disclosure.

To withdraw your consent with Novartis

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to and in the body of such request you must state your e-mail, full name, IS Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	<ul style="list-style-type: none">• Allow per session cookies• Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection

** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify Novartis as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Novartis during the course of my relationship with you.